To: Zeev Hed who wrote (1001 ) 10/10/1999 10:56:00 AM From: Mike McFarland Read Replies (1) | Respond to of 1438
Thanks, I'm sure I'll learn at least a few things from the thread. Of course the Ariad toxic is old news, so I don't mind bringing it up here (still long the stock, but patience is nearly run out) and I see there were already a smattering of posts regarding it earlier. My guess is that it is awfully late in the game to get much more out of shorting Ariad--and I have no love for the folks who do it, but if it adds to the squeeze potential later, I guess that would be okay <g>. The much higher volumes of the last few days and the lack of movement, up or down, in the stock, suggest to me that this thing is under pretty tight control now--and maybe some events in the next few months will make things clearer. It's unlikely that management would make such a horrible mistake twice--and if anybody at the company ever reads these boards, they already know they've at least one pissed off shareholder. I should think that Hoechst, which owns something like ten percent of Ariad (forget the exact figure) is more than a little disappointed in their investment. To be sure I'm a bit of a hypocrite--I'd have been delighted if a buck a share was the toxic induced low for the stock--it's pretty obvious now that calling the bottom in these things is next to impossible. And everything from here depends on securing partners, a lot of financing fears go away if they ink a deal. That said, time for me to start zipping through the thread. One final thought however--another read of their annual report reminds me that a lot of the details are not revealed--various terms and conditions--some of which may be kicking in now, some ten months after the series C toxics were issued. That may be important, and while I certainly would not suggest that anybody go long or short this one, their scientific papers of gene therapy regulation are a must read for anybody interested in that stuff--regardless of where the stock goes, it's remarkable stuff.